Literature DB >> 18401689

Impact of preoperative antiandrogen medication and nerve-sparing surgery on the outcome of radical prostatectomy.

J Hodzic1, P Jedrusik, T Reckwitz, H-J Knopf, K Golka.   

Abstract

OBJECTIVES: Radical prostatectomy in antiandrogen-medicated patients, as well as nerve-sparing surgery, has increased within recent years. We investigated the impact of antiandrogen medication on loss of blood and of nerve-sparing surgery on continence and potency.
METHODS: A total of 401 men who underwent radical prostatectomy between January 1995 and September 1999 at our clinic were asked about antiandrogenic medication prior to radical prostatectomy and about daily life activities, overall satisfaction, voiding ability, and sexual activities. Consumption of erythrocyte concentrates and cryoprecipitated plasma was taken from the records.
RESULTS: The average follow-up was 36 months. Seventy-two percent (n = 289) of our patients replied. Sixty-seven men (23%) who replied to our questionnaire had received antiandrogen medication prior to radical prostatectomy. In 53 (18%) of the men, the nerve-sparing technique was used. In antiandrogen-medicated patients, we observed a significantly elevated consumption of erythrocyte concentrates (antiandrogen-medicated 0.93, not antiandrogen-medicated 0.44; P = 0.013) and of cryoprecipitated plasma (antiandrogen-medicated 0.39, not antiandrogen-medicated 0.08; P = 0.010). Patients who underwent the nerve-sparing technique reported better results in daily life activities, general health status, International Prostate Symptom Score (IPSS), and continence.
CONCLUSION: Our results point to a higher quality of life in patients who had undergone nerve-sparing surgery.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18401689     DOI: 10.1007/s11255-008-9372-5

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN: 0301-1623            Impact factor:   2.370


  21 in total

1.  [Development of tumor selection based on pathological stage in clinically localized prostate carcinoma].

Authors:  J Noldus; M Graefen; P Hammerer; R P Henke; H Huland
Journal:  Urologe A       Date:  1998-03       Impact factor: 0.639

2.  [Nerve-sparing radical retropubic prostatectomy. Results of a patient survey].

Authors:  J Noldus; U Michl; M Graefen; A Haese; P Hammerer; S Fernandez; H Huland
Journal:  Urologe A       Date:  2001-03       Impact factor: 0.639

3.  Impotence following radical prostatectomy: insight into etiology and prevention.

Authors:  P C Walsh; P J Donker
Journal:  J Urol       Date:  1982-09       Impact factor: 7.450

4.  Bicalutamide ('Casodex') 150 mg in addition to standard care in patients with nonmetastatic prostate cancer: updated results from a randomised double-blind phase III study (median follow-up 5.1 y) in the early prostate cancer programme.

Authors:  M Wirth; C Tyrrell; K Delaere; M Sánchez-Chapado; J Ramon; D M A Wallace; J Hetherington; F Pina; C Heyns; T Borchers; T Morris; J Armstrong
Journal:  Prostate Cancer Prostatic Dis       Date:  2005       Impact factor: 5.554

5.  A prospective study of quantification of urinary incontinence and quality of life in patients undergoing radical retropubic prostatectomy.

Authors:  M Jønler; F A Madsen; P R Rhodes; M Sall; E M Messing; R C Bruskewitz
Journal:  Urology       Date:  1996-09       Impact factor: 2.649

6.  Long-term survival after hormonal therapy for stage D prostatic cancer.

Authors:  W G Reiner; W W Scott; J C Eggleston; P C Walsh
Journal:  J Urol       Date:  1979-08       Impact factor: 7.450

7.  Return of erections and urinary continence following nerve sparing radical retropubic prostatectomy.

Authors:  W J Catalona; J W Basler
Journal:  J Urol       Date:  1993-09       Impact factor: 7.450

8.  Patient-reported complications and follow-up treatment after radical prostatectomy. The National Medicare Experience: 1988-1990 (updated June 1993).

Authors:  F J Fowler; M J Barry; G Lu-Yao; A Roman; J Wasson; J E Wennberg
Journal:  Urology       Date:  1993-12       Impact factor: 2.649

9.  Nerve sparing radical prostatectomy: a different view.

Authors:  E S Geary; T E Dendinger; F S Freiha; T A Stamey
Journal:  J Urol       Date:  1995-07       Impact factor: 7.450

10.  Radical retropubic prostatectomy for localized carcinoma of the prostate in a large metropolitan hospital: changing trends over a 10-year period (1984-1994). Dallas Outcomes Research Group for Urological Disorders.

Authors:  S E Litwiller; B Djavan; B V Klopukh; J C Richier; C G Roehrborn
Journal:  Urology       Date:  1995-05       Impact factor: 2.649

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.